Patents Examined by Dale R Miller
  • Patent number: 11058713
    Abstract: The present invention provides an ophthalmic formulation consisting essentially of one or more pharmaceutically acceptable excipients; a pharmaceutically active compound that is capable of reducing the amount of inflammatory neutrophil product on the ocular surface; and optionally a second pharmaceutically active compound selected from the group consisting of a steroid, an anti-inflammatory agent, a mucolytic agent and a combination thereof. In particular, the present invention provides an ophthalmic formulation where the pharmaceutically active compound is capable of treating a clinical condition selected from the group consisting of inflammatory and immunological ocular surface disease that can cause symptoms of ocular discomfort, mucocellular aggregates/debris in tear film, symblepheron formation, fornix foreshortening, eyelid margin/conjunctival keratinization, corneal neovascularization/pannus, subconjunctival fibrosis, and herpetic eye disease.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: July 13, 2021
    Assignee: ADVAITE LLC.
    Inventors: Sandeep Jain, Karthik Musunuri
  • Patent number: 11058714
    Abstract: A method of inhibiting or reducing inflammation in a mammal comprises administering MCP or similar Gal-3 binding moiety with honokiol in a range of about 8-10:1, by weight, MCP to honokiol. By pursuing complimentary pathways, a synergistic combination is achieved, where the reduction or degree of inflammation inhibition is greater than would be expected by the added administration of these two agents. The inflammation may be manifested as gingivitis, which may be addressed by a preparation comprising honokiol and MCP, or an MCP equivalent, in the indicated range by weight, where they are in the form of an oral rinse, lozenge, sucking candy, toothpaste or tablet.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: July 13, 2021
    Assignee: ECONUGENICS, INC.
    Inventor: Isaac Eliaz
  • Patent number: 11052100
    Abstract: A nicotinamide riboside composition and preparation method thereof, the icotinamide riboside composition comprises nicotinamide riboside and/or a salt thereof and konjac glucomannan or rebaudioside A. The nicotinamide riboside composition provided by the present invention, used to increase the concentration of NAD in cells, thereby preventing and improving various unhealthy conditions caused by NAD deficiency. is stable in property and easy to store and transport.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: July 6, 2021
    Inventors: Rongzhao Fu, Zhenwei Li, Xinglin Guo
  • Patent number: 11046790
    Abstract: This invention describes a method for the purification of a hemicellulose extract produced for example through hot water extraction. Such extracts often contain large amounts of colloidal material which primarily consists of lignin and other phenolic compounds. These colloidal particles clog equipment such as ultrafiltration membranes, which deem the use of such equipment almost impossible. The unwanted material is very tacky at temperatures between 70 and 120° C. which makes it possible to adsorb it onto a variety of materials. Further, by using an adsorbing material that is wholly or partly contaminated with chemically alike material the purification process is greatly enhanced.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: June 29, 2021
    Assignee: CH-Bioforce Oy
    Inventors: Lari Vähäsalo, Nicholas Lax, Sebastian Von Schoultz
  • Patent number: 11046640
    Abstract: The present invention relates to novel compounds of the formula I, methods for their preparation and their use for treatment of diseases. The invention discloses the synthesis of levodopa (L-DOPA) esters by coupling polyhydroxy compounds or their derivatives to the L-DOPA carboxyl group. The synthesis allows to produce L-DOPA derivatives which are highly soluble in water as well as aqueous and biocompatible liquids and have an improved hydrolytic stability in water or aqueous and biocompatible media for an application over several days. The invention helps producing L-DOPA substances for applications in the fields of medicine, biology and medical engineering as well as in the pharmaceutical industry.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: June 29, 2021
    Assignee: BERLIREM GMBH
    Inventors: Johannes Tack, Ralf Wyrwa, Thorsten Laube, Matthias Schnalbelrauch, Juergen Weisser, Christoph Voelkel
  • Patent number: 11041009
    Abstract: An insulin conjugate comprising or consisting of a tri-valent sugar cluster is described. In particular aspects, the insulin conjugate displays a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: June 22, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Danqing Feng, Pei Huo, Ahmet Kekec, Songnian Lin, Christopher R. Moyes, Ravi Nargund, Brenda Pipik, Dmitri A. Pissarnitski, Lin Yan, Yuping Zhu
  • Patent number: 11033632
    Abstract: There is provided a molecule comprising a chain of seven or more contiguous units of 4,6-dideoxy-4-acylamido-?-pyranose, each pair of units joined by a C1-C2 or a C1-C3 link, the chain having a terminal end and a reducing end, wherein the pyranose ring in the unit of the chain most distal from the reducing end is linked to a cap structure. The cap structure is not a 4,6-dideoxy-4-acylamido-?-pyranose. There are also provided vaccine compositions comprising the molecule and methods of vaccinating an animal NI against infection by a Brucella organism, including methods of distinguishing between a vaccinated and an infected animal. There are further provided novel methods of detecting the presence in a sample of an anti-Brucella antibody.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: June 15, 2021
    Inventors: John McGiven, Laurence Howells, Lucy Duncombe, David Bundle, Satadru Sekhar Mandal, Susmita Sarkar
  • Patent number: 11026963
    Abstract: Provided herein are senolytic agents for selectively killing senescent cells that are associated with numerous pathologies and diseases, including age-related pathologies and diseases. As disclosed herein, senescent cell-associated diseases and disorders may be treated or prevented by administering at least one senolytic agent or pharmaceutical compositions thereof. The senescent cell-associated diseases or disorders treated or prevented by the methods described herein include, but are not limited to, cardiovascular diseases or disorders, cardiovascular diseases and disorders associated with arteriosclerosis, such as atherosclerosis, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), osteoarthritis, inflammatory diseases or disorders, autoimmune diseases or disorders, pulmonary diseases or disorders, neurological diseases or disorders, dermatological diseases or disorders, chemotherapeutic side effects, radiotherapy side effects, metastasis and metabolic diseases.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: June 8, 2021
    Assignee: Rubedo Life Sciences, Inc.
    Inventors: Mark A. Gallop, Julian Klein, Marco Quarta
  • Patent number: 11021507
    Abstract: The present invention provides a myricetin derivative, a preparation method thereof, a pharmaceutical composition containing the same, an application thereof for treating colitis, preventing and treating colitis-associated tumorigenesis and treating colorectal cancer, and an application thereof in preparing a composition for modulating activities of endoplasmic reticulum stress signaling molecules. The myricetin derivative disclosed herein has excellent water solubility, and has biological activities including inhibition of colitis, prevention and treatment of colitis-associated tumorigenesis, and treatment of colorectal cancer. The preparation method disclosed herein uses myricetrin as starting material which is economical and easily available. With the merits of low cost, high yield, high product purity and suitability for large-scale industrial production, the preparation method disclosed herein represents significant market value and economic prospects.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: June 1, 2021
    Inventors: Wenbao Li, Xianjun Qu, Feng Li, Liang Zhang, Shixiao Wang, Zhiyu Song, Feng Wang, Chong Yang, Huashi Guan
  • Patent number: 11021580
    Abstract: A process for manufacturing a cross-linked hyaluronic acid (HA) gel product is comprising the steps of: (a) preparing an aqueous mixture of HA and a cross-linking agent selected from multiepoxides and diepoxides; wherein the HA is dissolved in an aqueous solution containing 1-10% (w/w) inorganic hydroxide; and wherein the dissolved HA constitutes more than 10% (w/w) of the final mixture; and (b) subjecting the aqueous mixture to cross-linking conditions to allow the dissolved HA to react with the cross-linking agent so as to obtain a cross-linked HA gel product.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: June 1, 2021
    Assignee: Galderma Holding SA
    Inventor: Morgan Karlsson
  • Patent number: 11007214
    Abstract: A method for treating an eye disease of an affected eye includes administering to the affected eye of a subject in need of such treatment a steroidal-androgen-free composition containing a therapeutically effective amount of beta-cyclodextrin derivative. The eye disease can be meibomian gland dysfunction, blepharitis, or dry eye disease. A steroidal-androgen-free composition includes a beta-cyclodextrin derivative as a sole active pharmaceutical ingredient. The steroidal-androgen-free composition is an ophthalmic composition.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: May 18, 2021
    Inventors: Jinsong Ni, Rong Yang
  • Patent number: 11000538
    Abstract: The present specification relates to a composition containing novel (20S,24R)-6-O-?-D-glucopyranosyl(1?2)-?-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, a pharmaceutically acceptable salt thereof, a hydrate or a solvate thereof as an active ingredient. The composition exhibits an excellent exercise ability enhancing effect and anti-fatigue effect.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: May 11, 2021
    Inventors: Yong Deog Hong, Hyun Woo Jeong
  • Patent number: 11000537
    Abstract: The present specification relates to a composition containing novel ginsenoside, (20S,24R)-6-O-?-D-glucopyranosyl(1?2)-?-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, a pharmaceutically acceptable salt thereof, a hydrate or a solvate thereof as an active ingredient. The composition exhibits excellent effects in glycemic control, lipid metabolic control, cholesterol control, anti-obesity and blood circulation improvement.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: May 11, 2021
    Inventors: Yong Deog Hong, Hyun Woo Jeong
  • Patent number: 10987372
    Abstract: It is an object of the present invention to provide a novel therapeutic agent for hepatoma viruses. Specifically, the present invention relates to an anti-hepatoma virus agent, containing as an active ingredient a compound represented by the following Formula (I) or a pharmaceutically acceptable salt thereof: (wherein R1 is fluorine or hydrogen).
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: April 27, 2021
    Inventors: Masanori Ikeda, Midori Takeda, Masanori Baba, Nobuyuki Kato
  • Patent number: 10982010
    Abstract: The present invention relates to a process for extracting oxidised metal pollutants from treated cellulosic or lignocellulosic biomass to recover the metal. The treatment also generates a cellulosic or lignocellulosic biomass which can to be used as a feedstock for biofuel, for making cellulose containing materials, and provides a source of other renewable chemicals.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: April 20, 2021
    Assignee: IP2IPO Innovations Limited
    Inventors: Jason Hallett, Paul Fennell, Florence Gschwend, Agnieszka Brandt-Talbot, Geoffrey Kelsall
  • Patent number: 10973919
    Abstract: The invention relates to a vitamin preparation, especially for application to the skin, containing a physiologically effective amount of vitamin B12 or another precursor of coenzyme B12, a polysorbate as well as customary carrier substances for the formation of a gel matrix.
    Type: Grant
    Filed: July 23, 2013
    Date of Patent: April 13, 2021
    Assignee: Hilaltrade AG
    Inventor: Sven Reichwagen
  • Patent number: 10961223
    Abstract: The invention provides compounds for use in a method of treating and/or preventing a bacterial infection in a human or non-human mammal, said method comprising administration of said compound in combination with (either simultaneously, separately, or sequentially) a ?-lactam antibiotic, wherein said compound has the general formula I: (I) (wherein: Q is a lipophilic, zinc chelating moiety which is selective for Zn2+ ions and which comprises at least one, preferably two or more (e.g 2, 3 or 4), optionally substituted, unsaturated heterocyclic rings, e.g.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: March 30, 2021
    Inventors: Pål Rongved, Ove Alexander Høgmoen Åstrand, Ørjan Samuelsen, Christian Schnaars, Geir Kildahl-Andersen
  • Patent number: 10953038
    Abstract: The present invention relates to methods of managing weight, and treating overweight or obesity and treating or preventing diabetes in a subject in need thereof. In one embodiment, the method comprises the steps of (a) orally administering to the subject from about 0.7 g to about 4 g of crosslinked carboxymethylcellulose; and (b) orally administering to the subject at least about 100 mL of water per gram of crosslinked carboxymethylcellulose. Steps (a) and (b) are conducted prior to or with at least one meal per day.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: March 23, 2021
    Assignee: Gelesis LLC
    Inventors: Hassan Heshmati, Eyal S. Ron, Alessandro Sannino, Yishai Zohar
  • Patent number: 10941177
    Abstract: Provided are compounds of Formula I, as well as pharmaceutical compositions containing compounds of Formula I and methods for treating Orthomyxoviridae virus infections by administering these compounds. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: March 9, 2021
    Assignee: Gilead Sciences, Inc.
    Inventor: Michael O' Neil Hanrahan Clarke
  • Patent number: 10933086
    Abstract: Provided in the present invention is a novel use of composition containing a neoagarooligosaccharide mixture as an active ingredient. The neoagarooligosaccharide mixture and the like as an active ingredient of the composition according to the present invention can reduce the expression of RANKL, an osteoclast inducer, or IL-6, an inflammatory cytokine, and effectively inhibit differentiation of monocytes into osteoclasts. Thus, the composition according to the present invention may be used as a medicine or functional food for preventing, alleviating, or treating arthritis (especially rheumatoid arthritis). Further, the active ingredient of the composition according to the present invention can be obtained by an enzyme reaction between a readily available substrate such as agar or agarose and DagA as a beta-agarase derived from Streptomyces coelicolor. Thus, it can be produced at a relatively low cost and can easily be ingested by anyone because it has no side effects.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: March 2, 2021
    Assignee: DYNEBIO INC.
    Inventors: Je Hyeon Lee, Eun Joo Kim, Kyoung Woon Kim